Edery M, Rozakis-Adcock M, Goujon L, Finidori J, Lévi-Meyrueis C, Paly J, Djiane J, Postel-Vinay M C, Kelly P A
Institut National de la Santé et de la Recherche Médicale, Unité 344, Faculté Necker-Enfants Malades, Paris, France.
J Clin Invest. 1993 Mar;91(3):838-44. doi: 10.1172/JCI116304.
A single point mutation in the growth hormone (GH) receptor gene generating a Phe-->Ser substitution in the extracellular binding domain of the receptor has been identified in one family with Laron type dwarfism. The mutation was introduced by site-directed mutagenesis into cDNAs encoding the full-length rabbit GH receptor and the extracellular domain or binding protein (BP) of the human and rabbit GH receptor, and also in cDNAs encoding the full length and the extracellular domain of the related rabbit prolactin (PRL) receptor. All constructs were transiently expressed in COS-7 cells. Both wild type and mutant full-length rabbit GH and PRL receptors, as well as GH and prolactin BPs (wild type and mutant), were detected by Western blot in cell membranes and concentrated culture media, respectively. Immunofluorescence studies showed that wild type and mutant full-length GH receptors had the same cell surface and intracellular distribution and were expressed with comparable intensities. In contrast, all mutant forms (full-length receptors or BPs), completely lost their modify the synthesis ligand. These results clearly demonstrate that this point mutation (patients with Laron syndrome) does not modify the synthesis or the intracellular pathway of receptor proteins, but rather abolishes ability of the receptor or BP to bind GH and is thus responsible for the extreme GH resistance in these patients.
在一个患有拉伦型侏儒症的家族中,已鉴定出生长激素(GH)受体基因中的一个单点突变,该突变在受体的细胞外结合域产生了苯丙氨酸(Phe)到丝氨酸(Ser)的替换。通过定点诱变将该突变引入编码全长兔GH受体以及人和兔GH受体的细胞外结构域或结合蛋白(BP)的cDNA中,还引入编码相关兔催乳素(PRL)受体的全长和细胞外结构域的cDNA中。所有构建体均在COS-7细胞中瞬时表达。通过蛋白质印迹法分别在细胞膜和浓缩培养基中检测到野生型和突变型全长兔GH和PRL受体以及GH和催乳素BP(野生型和突变型)。免疫荧光研究表明,野生型和突变型全长GH受体具有相同的细胞表面和细胞内分布,且表达强度相当。相比之下,所有突变形式(全长受体或BP)完全丧失了修饰合成配体的能力。这些结果清楚地表明,这种点突变(拉伦综合征患者)不会改变受体蛋白的合成或细胞内途径,但会消除受体或BP结合GH的能力,因此导致这些患者出现极端的GH抵抗。